Blog
Aetion Generate 3.6: Privacy Meets Scientific Rigor in Real-World Evidence
At Aetion®, we ensure privacy concerns and compliance hurdles never stand in the way of ...
Blog
Feature Spotlight: Transforming RWD Management with Measures Assistant (Beta)
Real-world data (RWD) is the lifeblood of modern healthcare research, driving ...
Blog
FDA Expands Dupixent Approval for Adolescents with Chronic Rhinosinusitis with Nasal Polyps, Leveraging RWE Powered by Aetion® Substantiate
Blog authored by:
Blog
Driving Innovation in HTA Decision-Making: Aetion participates in RWE4Decisions' 2024 Stakeholder Actions
On November 14th, RWE4Decisions hosted its annual Symposium, this year focusing on how to ...
Blog
Own the Future of Healthcare: Aetion’s AI/ML Tools Turn Data Into Impact
Healthcare stands at a crossroads. The pressure to deliver better care at lower costs is ...
Blog
Applying AI to RWE and Drug Development
With applications abound, AI is poised to change how RWD/RWE teams operate and how ...
Blog
What’s Next for Healthcare in 2025: Emerging Threats, GLP-1 Inhibitors, AI, and the Power of RWE
As 2024 comes to a close and 2025 gets going, major changes in healthcare and drug ...
Blog
How RWE can Impact R&D and Beyond
Real-world data (RWD) and real-world evidence (RWE) continue to positively impact drug ...
Blog
Bringing Patients Front and Center in RWD/RWE
The ultimate goal of using real-world data (RWD) to generate real-world evidence (RWE) is ...
Blog
Webinar recap: The Goldilocks problem in oncology RWD: choosing the data that’s ‘just right’
We all know that, in the story of Goldilocks and the Three Bears, it took the young girl ...
Blog
Advancing Pharmacoepidemiology at ICPE 2024
Aetion joins experts from around the world at ICPE 2024 to discuss advances in ...
Blog
Efficient Synthesis of Complex Health Data
Blog authored by Lucy Mosquera (Sr. Director, Generate Operations and Data Science) and ...
Blog
Advancing SMA Treatment: How Real-World Evidence Supports Regulatory Decisions
Spinal Muscular Atrophy (SMA) is a rare and debilitating neuromuscular disease affecting ...
Blog
Quality, Rigor, and Transparency: The RWE Imperative
Over the past year, news stories have focused on high-profile missteps or fraud in the ...
Blog
The Evolving Role of Observational Studies in Healthcare: Enhancing Payer Utility and Impact
Blog authored by Ashley Jaksa (VP, Scientific Strategy & Partnerships) and Pat Arena ...
Blog
Navigating the European Union's Medical Device Regulation (MDR)
On May 26, 2021 the European Union’s (EU) Medical Device Regulation (MDR) became ...
Blog
How to unleash the replicability potential of synthetic data
In today's data-driven world, the need for innovative solutions to evolve alongside the ...
Blog
Key Takeaways from the public workshop, “Advancing Real-World Data to Generate Regulatory Grade Real-World Evidence in Oncology”
By Inish O’Doherty and Purva Jain
Blog
FDA releases draft guidance on non-interventional studies for drug and biological products
The Food and Drug Administration (FDA) continues to advance its RWE Program, this time ...
Blog
Aetion’s comments to FDA on recent draft guidance on the substantial evidence standard
This week, Aetion submitted a letter to FDA commenting on the Agency’s recent draft ...
Blog
Research Spotlight: A Deep Dive into a Real-World Reproducibility Study
Both real-world data (RWD) and real-world evidence (RWE) studies continue to effectively ...
Blog
Partnering to enhance Japanese RWD at a global scale: A Q&A with JMDC
JMDC, a leading Japanese health big data firm, and Aetion® recently announced a ...
Blog
Research Spotlight: Navigating Treatment Effectiveness in Rare Oncology with External Control Cohorts
Real-world data (RWD) has proven to be a pivotal tool in understanding patient treatment ...
Blog
What I saw at DIA RWE 2023
I am just back from Baltimore, Maryland, where I had the joy of attending DIA’s ...